Skip to search formSkip to main contentSkip to account menu

zibotentan

Known as: 3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pridine-3- sulfonamide 
An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

ZD4054

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The contribution of endothelin-1 in colorectal cancer & the efficacy of the novel endothelin receptor antagonist ZD4054
The overall aims of this thesis are: to determine the cellular response to ET-1 and effects of receptor antagonism on… 
2013
2013
Endothelin A Receptor Antagonist Zibotentan ( ZD 4054 ) inColorectal Cancer : APreclinical Study
Endothelin 1 (ET-1) is overexpressed in cancer, contributing to disease progression. We previously showed that ET-1… 
2011
2011
Prostate cancer: A rocky road to overcoming castration resistance
a rocky road to overcoming castration resistance efforts to expand the therapeutic armamentarium for castrationresistant prostate… 
2010
2010
Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy…
4664 Background: The combination of docetaxel and prednisone is the current standard care for patients with advanced castration… 
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…